Swiss banking giant UBS on Tuesday posted $770 million in fourth-quarter net profit, compared with a mean forecast of $886.4 ...

UBS Group AG said it aims to buy back up to $3 billion of its own shares this year, signaling confidence as it awaits a ...

In the final month of 2024, exports of watches between 200 and 500 Swiss francs were the hardest hit, with a drop of 13.2 ...

The Japanese yen and the Swiss franc gained while the U.S. dollar fell against major currencies on Monday amid a selloff in ...

Switzerland’s top criminal court convicted a multinational company for the first time, ruling against commodities trader ...

Swiss biopharma company BioVersys said on Wednesday it had launched an initial public offering on the SIX stock exchange priced at 36 Swiss francs ($39.84) per share.

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Analysts at Rabobank predict the Euro to Swiss franc exchange rate (EUR/CHF) will face downward pressure in the coming months. According to analysts at CIBC Capital Markets, following the ...

Q: What is the Swiss Franc worth against the Dirham? A: One Swiss Franc is worth 4.047 Dirhams today Q: Is the Swiss Franc going up or down against the Dirham? A: Today's exchange rate (4.047 ...

Battles lines drawn on the USD/CHF short-term technical charts. Technical Outlook: In last month’s Swiss Franc Short-term Outlook we noted that USD/CHF had, “extending into uptrend resistance near the ...

ZURICH, Jan 29 (Reuters) - Swiss biopharma company BioVersys said on Wednesday it had launched an initial public offering on the SIX stock exchange priced at 36 Swiss francs ($39.84) per share.